Dovato (dolutegravir/lamivudine) is indicated for use as a complete regimen for the treatment of HIV 1 infection. However, in specific clinical situations where an intensification of HIV treatment is needed, coadministration with zidovudine would be possible from a pharmacokinetic standpoint. The European product label for Dovato advises that no dose adjustment is necessary with zidovudine. No interaction is expected with dolutegravir. No clinically significant alterations in lamivudine or zidovudine pharmacokinetics were observed with coadministration of zidovudine (200 mg, single dose) and lamivudine (300 mg single dose).